Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2822535 | 0.94 | MEN1 (0.31) | MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL2821863 | 0.81 | ALDH1A1 (0.41) | MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL2826304 | 0.78 | ALDH1A1 (0.34) | MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL2826984 | 0.76 | ALDH1A1 (0.39) | MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL2822658 | 0.75 | ALDH1A1 (0.39) | MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL2826368 | 0.75 | MAPT (0.40) | MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL2825363 | 0.72 | PDE5A (0.40) | MEN1KMT2AMAPTSMN1; SMN2DRD3 | |
| SCHEMBL2824358 | 0.67 | ALDH1A1 (0.43) | MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL34474666 | 0.67 | NR1H2 (0.46) | MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL2826105 | 0.66 | PIK3CD (0.33) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2226322-B1 | IMIDAZOLE CARBONYL COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2015-01-21 | — | — | EP | disclosed |
| US-8927588-B2 | Imidazole carbonyl compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-01-06 | — | — | US | disclosed |
| US-20140073622-A1 | IMIDAZOLE CARBONYL COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-03-13 | — | — | US | disclosed |
| US-8536197-B2 | Imidazole carbonyl compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-09-17 | — | — | US | disclosed |
| US-20100311966-A1 | IMIDAZOLE CARBONYL COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-12-09 | — | — | US | disclosed |
| EP-2226322-A1 | IMIDAZOLE CARBONYL COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2010-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311966-A1 | IMIDAZOLE CARBONYL COMPOUND | TOP1, TOP2B, TOP2A | MEN1 3960/4885KMT2A 847/4885MAPT 1455/4885 |
| US-20140073622-A1 | IMIDAZOLE CARBONYL COMPOUND | TOP1, TOP2B, TOP2A | MEN1 3629/4885KMT2A 1335/4885MAPT 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.